Sensors for Medicine and Technology gets funds for implanted home glucose monitor
This article was originally published in Clinica
US company SMSI (Sensors for Medicine and Technology) has received a $15m venture capital cash injection to fund clinical trials of its novel glucose sensor technology. The Germantown, Maryland company is currently overseeing late preclinical stage development of the continuous monitoring device, and expects to file an investigational device exemption (IDE) for it in 2006. "The process to commercialisation should take another two years or so," president and CEO Marc Schneebaum told Clinica, adding that the trials are designed to demonstrate that the system is accurate enough to replace standard home blood glucose monitoring.